<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39337843</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-1729</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>23</Day></PubDate></JournalIssue><Title>Life (Basel, Switzerland)</Title><ISOAbbreviation>Life (Basel)</ISOAbbreviation></Journal><ArticleTitle>A Histological Analysis and Detection of Complement Regulatory Protein CD55 in SARS-CoV-2 Infected Lungs.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1058</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/life14091058</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A complement imbalance in lung alveolar tissue can play a deteriorating role in COVID-19, leading to acute respiratory distress syndrome (ARDS). CD55 is a transmembrane glycoprotein that inhibits the activation of the complement system at the intermediate cascade level, blocking the activity of the C3 convertase.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">In our study, lung specimens from COVID-19 and ARDS-positive COVID+/ARDS+ patients were compared with COVID-19 and ARDS-negative COVID-/ARDS- as well as COVID-/ARDS+ patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Histochemical staining and immunolabeling of CD55 protein were performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The COVID-/ARDS- specimen showed higher expression and homogeneous distribution of glycosaminoglycans as well as compactly arranged elastic and collagen fibers of the alveolar walls in comparison to ARDS-affected lungs. In addition, COVID-/ARDS- lung tissues revealed stronger and homogenously distributed CD55 expression on the alveolar walls in comparison to the disrupted COVID-/ARDS+ lung tissues.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Even though the collapse of the alveolar linings and the accumulation of cellular components in the alveolar spaces were characteristic of COVID+/ARDS+ lung tissues, evaluating CD55 expression could be relevant to understand its relation to the disease. Furthermore, targeting CD55 upregulation as a potential therapy could be an option for post-infectious complications of COVID-19 and other inflammatory lung diseases in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Silawal</LastName><ForeName>Sandeep</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Anatomy and Cell Biology, Paracelsus Medical University, Nuremberg and Salzburg, General Hospital Nuremberg, Prof. Ernst Nathan Str. 1, 90419 Nuremberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gögele</LastName><ForeName>Clemens</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-7086-9743</Identifier><AffiliationInfo><Affiliation>Institute of Anatomy and Cell Biology, Paracelsus Medical University, Nuremberg and Salzburg, General Hospital Nuremberg, Prof. Ernst Nathan Str. 1, 90419 Nuremberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelikan</LastName><ForeName>Petr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute for Pathology, Paracelsus Medical University, Nuremberg, General Hospital, Prof. Ernst Nathan Str. 1, 90419 Nuremberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werner</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Anatomy and Cell Biology, Paracelsus Medical University, Nuremberg and Salzburg, General Hospital Nuremberg, Prof. Ernst Nathan Str. 1, 90419 Nuremberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levidou</LastName><ForeName>Georgia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-1398-178X</Identifier><AffiliationInfo><Affiliation>Institute for Pathology, Paracelsus Medical University, Nuremberg, General Hospital, Prof. Ernst Nathan Str. 1, 90419 Nuremberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahato</LastName><ForeName>Raman</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Emergency and Intensive Care Medicine, Klinikum Ernst von Bergmann, Charlottenstraße 72, 14467 Potsdam, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulze-Tanzil</LastName><ForeName>Gundula</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-9807-9532</Identifier><AffiliationInfo><Affiliation>Institute of Anatomy and Cell Biology, Paracelsus Medical University, Nuremberg and Salzburg, General Hospital Nuremberg, Prof. Ernst Nathan Str. 1, 90419 Nuremberg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>no number</GrantID><Agency>Dr. Ernst &amp; Anita foundation</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Life (Basel)</MedlineTA><NlmUniqueID>101580444</NlmUniqueID><ISSNLinking>2075-1729</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ARDS</Keyword><Keyword MajorTopicYN="N">CD55</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">histology</Keyword><Keyword MajorTopicYN="N">immunofluorescence</Keyword><Keyword MajorTopicYN="N">lungs</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39337843</ArticleId><ArticleId IdType="pmc">PMC11432792</ArticleId><ArticleId IdType="doi">10.3390/life14091058</ArticleId><ArticleId IdType="pii">life14091058</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H., Wang T., Zhang X., Chen H., Yu H., et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Investig. 2020;130:2620–2629. doi: 10.1172/JCI137244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137244</ArticleId><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang G., Liu Z., Chen D. Human coronaviruses: Origin, host and receptor. J. Clin. Virol. 2022;155:105246. doi: 10.1016/j.jcv.2022.105246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2022.105246</ArticleId><ArticleId IdType="pmc">PMC9301904</ArticleId><ArticleId IdType="pubmed">35930858</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., McGoogan J.M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72,314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–1242. doi: 10.1001/jama.2020.2648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Tisoncik J.R., Korth M.J., Simmons C.P., Farrar J., Martin T.R., Katze M.G. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 2012;76:16–32. doi: 10.1128/MMBR.05015-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MMBR.05015-11</ArticleId><ArticleId IdType="pmc">PMC3294426</ArticleId><ArticleId IdType="pubmed">22390970</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangalmurti N., Hunter C.A. Cytokine Storms: Understanding COVID-19. Immunity. 2020;53:19–25. doi: 10.1016/j.immuni.2020.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.06.017</ArticleId><ArticleId IdType="pmc">PMC7321048</ArticleId><ArticleId IdType="pubmed">32610079</ArticleId></ArticleIdList></Reference><Reference><Citation>Gralinski L.E., Sheahan T.P., Morrison T.E., Menachery V.D., Jensen K., Leist S.R., Whitmore A., Heise M.T., Baric R.S. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio. 2018;9:e01753-18. doi: 10.1128/mBio.01753-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01753-18</ArticleId><ArticleId IdType="pmc">PMC6178621</ArticleId><ArticleId IdType="pubmed">30301856</ArticleId></ArticleIdList></Reference><Reference><Citation>Gralinski L.E., Menachery V.D. Return of the Coronavirus: 2019-nCoV. Viruses. 2020;12:135. doi: 10.3390/v12020135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12020135</ArticleId><ArticleId IdType="pmc">PMC7077245</ArticleId><ArticleId IdType="pubmed">31991541</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoermer K.A., Morrison T.E. Complement and viral pathogenesis. Virology. 2011;411:362–373. doi: 10.1016/j.virol.2010.12.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2010.12.045</ArticleId><ArticleId IdType="pmc">PMC3073741</ArticleId><ArticleId IdType="pubmed">21292294</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvelli J., Demaria O., Vély F., Batista L., Benmansour N.C., Fares J., Carpentier S., Thibult M.-L., Morel A., Remark R., et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature. 2020;588:146–150. doi: 10.1038/s41586-020-2600-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2600-6</ArticleId><ArticleId IdType="pmc">PMC7116884</ArticleId><ArticleId IdType="pubmed">32726800</ArticleId></ArticleIdList></Reference><Reference><Citation>Risitano A.M., Mastellos D.C., Huber-Lang M., Yancopoulou D., Garlanda C., Ciceri F., Lambris J.D. Complement as a target in COVID-19? Nat. Rev. Immunol. 2020;20:343–344. doi: 10.1038/s41577-020-0320-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0320-7</ArticleId><ArticleId IdType="pmc">PMC7187144</ArticleId><ArticleId IdType="pubmed">32327719</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzali B., Noris M., Lambrecht B.N., Kemper C. The state of complement in COVID-19. Nat. Rev. Immunol. 2022;22:77–84. doi: 10.1038/s41577-021-00665-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00665-1</ArticleId><ArticleId IdType="pmc">PMC8672651</ArticleId><ArticleId IdType="pubmed">34912108</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouaki Benmansour N., Carvelli J., Vivier E. Complement cascade in severe forms of COVID-19: Recent advances in therapy. Eur. J. Immunol. 2021;51:1652–1659. doi: 10.1002/eji.202048959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202048959</ArticleId><ArticleId IdType="pmc">PMC8250085</ArticleId><ArticleId IdType="pubmed">33738806</ArticleId></ArticleIdList></Reference><Reference><Citation>Varsano S., Frolkis I., Ophir D. Expression and distribution of cell-membrane complement regulatory glycoproteins along the human respiratory tract. Am. J. Respir. Crit. Care Med. 1995;152:1087–1093. doi: 10.1164/ajrccm.152.3.7545058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.152.3.7545058</ArticleId><ArticleId IdType="pubmed">7545058</ArticleId></ArticleIdList></Reference><Reference><Citation>Janeway C.A., Jr., Travers P., Walport M., Shlomchik M. Immunobiology: The Immune System in Health and Disease. 5th ed. Garland Science; New York, NY, USA: 2001.</Citation></Reference><Reference><Citation>Lage S.L., Rocco J.M., Laidlaw E., Rupert A., Galindo F., Kellogg A., Kumar P., Poon R., Wortmann G.W., Lisco A., et al. Activation of Complement Components on Circulating Blood Monocytes From COVID-19 Patients. Front. Immunol. 2022;13:815833. doi: 10.3389/fimmu.2022.815833.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.815833</ArticleId><ArticleId IdType="pmc">PMC8892247</ArticleId><ArticleId IdType="pubmed">35250994</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandya P.H., Fisher A.J., Mickler E.A., Temm C.J., Lipking K.P., Gracon A., Rothhaar K., Sandusky G.E., Murray M., Pollok K., et al. Hypoxia-Inducible Factor-1α Regulates CD55 in Airway Epithelium. Am. J. Respir. Cell Mol. Biol. 2016;55:889–898. doi: 10.1165/rcmb.2015-0237OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2015-0237OC</ArticleId><ArticleId IdType="pmc">PMC5248950</ArticleId><ArticleId IdType="pubmed">27494303</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao M.T., Ellsworth C.R., Qin X. Emerging role of complement in COVID-19 and other respiratory virus diseases. Cell. Mol. Life Sci. 2024;81:94. doi: 10.1007/s00018-024-05157-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-024-05157-8</ArticleId><ArticleId IdType="pmc">PMC10874912</ArticleId><ArticleId IdType="pubmed">38368584</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X., Han M., Li T., Sun W., Wang D., Fu B., Zhou Y., Zheng X., Yang Y., Li X., et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl. Acad. Sci. USA. 2020;117:10970–10975. doi: 10.1073/pnas.2005615117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2005615117</ArticleId><ArticleId IdType="pmc">PMC7245089</ArticleId><ArticleId IdType="pubmed">32350134</ArticleId></ArticleIdList></Reference><Reference><Citation>Dho S.H., Lim J.C., Kim L.K. Beyond the Role of CD55 as a Complement Component. Immune Netw. 2018;18:e11. doi: 10.4110/in.2018.18.e11.</Citation><ArticleIdList><ArticleId IdType="doi">10.4110/in.2018.18.e11</ArticleId><ArticleId IdType="pmc">PMC5833118</ArticleId><ArticleId IdType="pubmed">29503741</ArticleId></ArticleIdList></Reference><Reference><Citation>Silawal S., Kohl B., Shi J., Schulze-Tanzil G. Complement Regulation in Human Tenocytes under the Influence of Anaphylatoxin C5a. Int. J. Mol. Sci. 2021;22:3105. doi: 10.3390/ijms22063105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22063105</ArticleId><ArticleId IdType="pmc">PMC8003014</ArticleId><ArticleId IdType="pubmed">33803624</ArticleId></ArticleIdList></Reference><Reference><Citation>Angeles Montero-Fernandez M., Pardo-Garcia R. Histopathology features of the lung in COVID-19 patients. Diagn. Histopathol. 2021;27:123–127. doi: 10.1016/j.mpdhp.2020.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mpdhp.2020.11.009</ArticleId><ArticleId IdType="pmc">PMC7717771</ArticleId><ArticleId IdType="pubmed">33312229</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomashefski J.F., Jr. Pulmonary pathology of acute respiratory distress syndrome. Clin. Chest Med. 2000;21:435–466. doi: 10.1016/S0272-5231(05)70158-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0272-5231(05)70158-1</ArticleId><ArticleId IdType="pubmed">11019719</ArticleId></ArticleIdList></Reference><Reference><Citation>Menter T., Haslbauer J.D., Nienhold R., Savic S., Hopfer H., Deigendesch N., Frank S., Turek D., Willi N., Pargger H., et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology. 2020;77:198–209. doi: 10.1111/his.14134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/his.14134</ArticleId><ArticleId IdType="pmc">PMC7496150</ArticleId><ArticleId IdType="pubmed">32364264</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi A., Majumdar A., Parameswaran H., Bartolák-Suki E., Suki B. Proteoglycans maintain lung stability in an elastase-treated mouse model of emphysema. Am. J. Respir. Cell Mol. Biol. 2014;51:26–33. doi: 10.1165/rcmb.2013-0179OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2013-0179OC</ArticleId><ArticleId IdType="pmc">PMC4091854</ArticleId><ArticleId IdType="pubmed">24450478</ArticleId></ArticleIdList></Reference><Reference><Citation>Vittal R., Fisher A.J., Thompson E.L., Cipolla E.M., Gu H., Mickler E.A., Varre A., Agarwal M., Kim K.K., Vasko M.R., et al. Overexpression of Decay Accelerating Factor Mitigates Fibrotic Responses to Lung Injury. Am. J. Respir. Cell Mol. Biol. 2022;67:459–470. doi: 10.1165/rcmb.2021-0463OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2021-0463OC</ArticleId><ArticleId IdType="pmc">PMC9564933</ArticleId><ArticleId IdType="pubmed">35895592</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge X., Yu Z., Guo X., Li L., Ye L., Ye M., Yuan J., Zhu C., Hu W., Hou Y. Complement and complement regulatory proteins are upregulated in lungs of COVID-19 patients. Pathol. Res. Pract. 2023;247:154519. doi: 10.1016/j.prp.2023.154519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prp.2023.154519</ArticleId><ArticleId IdType="pmc">PMC10165854</ArticleId><ArticleId IdType="pubmed">37244049</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal P., Nawadkar R., Ojha H., Kumar J., Sahu A. Complement Evasion Strategies of Viruses: An Overview. Front. Microbiol. 2017;8:1117. doi: 10.3389/fmicb.2017.01117.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.01117</ArticleId><ArticleId IdType="pmc">PMC5472698</ArticleId><ArticleId IdType="pubmed">28670306</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Johnson J.B., Parks G.D. Parainfluenza virus 5 upregulates CD55 expression to produce virions with enhanced resistance to complement-mediated neutralization. Virology. 2016;497:305–313. doi: 10.1016/j.virol.2016.07.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2016.07.030</ArticleId><ArticleId IdType="pmc">PMC6054313</ArticleId><ArticleId IdType="pubmed">27505156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward T., Pipkin P., Clarkson N., Stone D., Minor P., Almond J. Decay-accelerating factor CD55 is identified as the receptor for echovirus 7 using CELICS, a rapid immuno-focal cloning method. EMBO J. 1994;13:5070–5074. doi: 10.1002/j.1460-2075.1994.tb06836.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1994.tb06836.x</ArticleId><ArticleId IdType="pmc">PMC395453</ArticleId><ArticleId IdType="pubmed">7525274</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Yang Q., Liu C., Wang G., Song H., Shang G., Peng R., Qu X., Liu S., Cui Y., et al. Molecular basis of differential receptor usage for naturally occurring CD55-binding and -nonbinding coxsackievirus B3 strains. Proc. Natl. Acad. Sci. USA. 2022;119:e2118590119. doi: 10.1073/pnas.2118590119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2118590119</ArticleId><ArticleId IdType="pmc">PMC8794823</ArticleId><ArticleId IdType="pubmed">35046043</ArticleId></ArticleIdList></Reference><Reference><Citation>Malekshahi Z., Bernklau S., Schiela B., Koske I., Banki Z., Stiasny K., Harris C.L., Würzner R., Stoiber H. Incorporation of CD55 into the Zika Viral Envelope Contributes to Its Stability against Human Complement. Viruses. 2021;13:510. doi: 10.3390/v13030510.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13030510</ArticleId><ArticleId IdType="pmc">PMC8003375</ArticleId><ArticleId IdType="pubmed">33808725</ArticleId></ArticleIdList></Reference><Reference><Citation>Vastrad B., Vastrad C., Tengli A. Identification of potential mRNA panels for severe acute respiratory syndrome coronavirus 2 (COVID-19) diagnosis and treatment using microarray dataset and bioinformatics methods. 3 Biotech. 2020;10:422. doi: 10.1007/s13205-020-02406-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13205-020-02406-y</ArticleId><ArticleId IdType="pmc">PMC7679428</ArticleId><ArticleId IdType="pubmed">33251083</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu H., Mickler E.A., Cummings O.W., Sandusky G.E., Weber D.J., Gracon A., Woodruff T., Wilkes D.S., Vittal R. Crosstalk between TGF-β1 and complement activation augments epithelial injury in pulmonary fibrosis. FASEB J. 2014;28:4223–4234. doi: 10.1096/fj.13-247650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.13-247650</ArticleId><ArticleId IdType="pmc">PMC4202097</ArticleId><ArticleId IdType="pubmed">24958208</ArticleId></ArticleIdList></Reference><Reference><Citation>Posch W., Vosper J., Noureen A., Zaderer V., Witting C., Bertacchi G., Gstir R., Filipek P.A., Bonn G.K., Huber L.A., et al. C5aR inhibition of nonimmune cells suppresses inflammation and maintains epithelial integrity in SARS-CoV-2–infected primary human airway epithelia. J. Allergy Clin. Immunol. 2021;147:2083–2097.e6. doi: 10.1016/j.jaci.2021.03.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2021.03.038</ArticleId><ArticleId IdType="pmc">PMC8056780</ArticleId><ArticleId IdType="pubmed">33852936</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastellos D.C., Ricklin D., Lambris J.D. Clinical promise of next-generation complement therapeutics. Nat. Rev. Drug Discov. 2019;18:707–729. doi: 10.1038/s41573-019-0031-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-019-0031-6</ArticleId><ArticleId IdType="pmc">PMC7340853</ArticleId><ArticleId IdType="pubmed">31324874</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>